You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

Article metrics

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 20222103
Nov 20223707
Dec 20225207
Jan 20234002
Feb 20233003
Mar 20233406
Apr 20232402
May 20232702
Jun 20231702
Jul 2023805
Aug 20232805
Sep 20231204
Oct 20232202
Nov 20231403
Dec 20234303
Jan 20241002
Feb 20241801
Mar 202437013
Apr 20241105
Total485077